EBOS ANNOUNCES SETTLEMENT OF $1.1B SYMBION ACQUISITION
AND AN OVERSUBSCRIBED RIGHTS OFFER
News release
5 July 2013
The Directors of EBOS Group Limited ("EBOS") are pleased to advise the
successful completion today of the NZ$1.1bn acquisition of Zuellig Healthcare
Holdings Australia Pty Ltd ("Symbion"). Settlement of the transaction follows
the conclusion of its NZ$149.1 million 7:20 pro-rata renounceable rights
issue which closed on 1 July 2013 substantially oversubscribed.
EBOS Managing Director, Mark Waller said: "The settlement of this acquisition
concludes the successful completion of EBOS'' largest acquisition to date.
This acquisition transforms EBOS into the largest diversified Australasian
marketer, wholesaler and distributor of healthcare, medical and
pharmaceutical products by revenue and a leading Australasian animal care
products marketer, wholesaler and distributor."
"The settlement marks the beginning of an exciting phase in EBOS''s evolution
with management and board focus moving to capitalising on the opportunities a
combination of these two leading businesses provides to generate long term
value for our shareholders."
"Whilst combined revenue is initially expected to be $6 billion, looking
forward, the increased scale and complementary nature of both businesses can
be expected to open up additional revenue opportunities and operational
efficiencies."
In relation to the capital raising Mr Waller noted: "The very strong
participation rate by existing shareholders under the entitlement offer,
together with the substantial level of oversubscriptions received of
approximately NZ$60 million, were very pleasing and another strong
endorsement of the transaction."
For the purposes of the NZSX Listing Rules, EBOS advises the following:
o Subscriptions received under entitlements: 22,154,203 ordinary shares
totalling NZ$144.0 million, representing a take-up of entitlements of 97%;
o Under subscription for entitlements: 786,983 ordinary shares totalling
NZ$5.1 million, representing a shortfall in take-up of entitlements of 3%;
o Applications for additional shares under the oversubscription facility:
9,266,223 ordinary shares totalling NZ$60.2 million;
o The rights issue was oversubscribed by 37% taking into account aggregate
applications received (inclusive of applications for additional shares
received under the oversubscription facility).
EBOS will allocate all shortfall shares to applicants for additional shares
in accordance with the terms of the oversubscription facility. The new
shares are expected to be issued on 5 July 2013, with shareholder statements
to be dispatched shortly thereafter.
ENDS
Mark Waller
Managing Director/CEO
EBOS Group Ltd
DDI: (03) 339-5061
Mobile: 021-368746
For media inquiries:
Geoff Senescall
Senescall Akers Limited
Mobile: 021- 481234
End CA:00238281 For:EBO Type:ASSET Time:2013-07-05 16:14:40